Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.

Anthonie J. Wekken, van der, Justine L. Kuiper, Danielle A. M. Heideman, Ed Schuuring, Wim Timens, Erik Thunnissen, Harry J. M. Groen, Egbert F. Smit

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)3526
JournalCancer Research
Issue number8
Publication statusPublished - 15-Apr-2013
Event104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) - Washington, Washington, United States
Duration: 6-Apr-201310-Apr-2013

Cite this